European heart journal. Digital health · 2025
Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Garcia Rodrigue, Gras Daniel, Mansourati Jacques, Defaye Pascal, Bisson Arnaud, Boveda Serge, Durocher Lisa, Gandjbakhch Estelle, Gras Matthieu, Gueffet Jean-Pierre, Himbert Caroline, Jacon Peggy, Khattar Pierre, Lequeux Benoit, Li Anthony, Mansourati Vincent, Minois Damien, Marijon Eloi, Pierre Bertrand, Ragot Stéphanie, Probst Vincent, Degand Bruno
Аннотация
AIMS: HeartLogic, an algorithm in implanted devices, predicts heart failure (HF) episodes via a remotely monitored index, aiding proactive congestion treatment to prevent acute decompensation. This study assessed the efficacy and safety of pre-emptive HF management using the HeartLogic index.
METHODS AND RESULTS: The HeartLogic France Cohort Study is a prospective multicentre investigation involving 310 HF patients with implanted cardioverter defibrillators enrolled from 10 French centres. The HeartLogic™ index was monitored for 12 months, and when the index reached ≥16, patients were contacted to adjust HF treatment. The primary endpoint was unscheduled hospitalization for HF. An independent blinded committee adjudicated the events. A total of 309 patients (65 ± 10 years old; 83.5% male, left ventricular ejection fraction 31 ± 9%) were included in the analysis. Ischemic cardiomyopathy was present in 61.2% (n = 189) of the patients, and 52.8% (n = 163) had a cardiac resynchronization therapy device. During follow-up, 406 alerts occurred in 158 patients (1.33 alerts/patient-year), resulting in treatment modification in 39.6% of alerts. A total of 24 unplanned HF hospitalizations occurred in 19 (6.1%) patients. Sixteen (66.7%) of those hospitalizations were preceded by a HeartLogic alert, of which 14 (87.5%) triggered a drug modification before hospitalization. Eighteen deaths (5.8%) occurred, including 10 due to cardiovascular causes. An increase in creatinine ≥30% and symptomatic hypotension were reported in two patients. Hyperkalemia and hyponatremia were not observed.
CONCLUSION: Pre-emptive HF management guided by the HeartLogic index was associated with low rates of unplanned hospitalizations and adverse events over a 12-month follow-up period.
STUDY REGISTRATION: ClinicalTrials.gov, ID: NCT04619888.
METHODS AND RESULTS: The HeartLogic France Cohort Study is a prospective multicentre investigation involving 310 HF patients with implanted cardioverter defibrillators enrolled from 10 French centres. The HeartLogic™ index was monitored for 12 months, and when the index reached ≥16, patients were contacted to adjust HF treatment. The primary endpoint was unscheduled hospitalization for HF. An independent blinded committee adjudicated the events. A total of 309 patients (65 ± 10 years old; 83.5% male, left ventricular ejection fraction 31 ± 9%) were included in the analysis. Ischemic cardiomyopathy was present in 61.2% (n = 189) of the patients, and 52.8% (n = 163) had a cardiac resynchronization therapy device. During follow-up, 406 alerts occurred in 158 patients (1.33 alerts/patient-year), resulting in treatment modification in 39.6% of alerts. A total of 24 unplanned HF hospitalizations occurred in 19 (6.1%) patients. Sixteen (66.7%) of those hospitalizations were preceded by a HeartLogic alert, of which 14 (87.5%) triggered a drug modification before hospitalization. Eighteen deaths (5.8%) occurred, including 10 due to cardiovascular causes. An increase in creatinine ≥30% and symptomatic hypotension were reported in two patients. Hyperkalemia and hyponatremia were not observed.
CONCLUSION: Pre-emptive HF management guided by the HeartLogic index was associated with low rates of unplanned hospitalizations and adverse events over a 12-month follow-up period.
STUDY REGISTRATION: ClinicalTrials.gov, ID: NCT04619888.